A carregar...
Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies
Large B cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the majority of cases. However, patients with primary refractory or relapsed disease have historically had limited treatment options. Two gene-modified chimeric antigen receptor (CAR)-T cell therapies have now been approved...
Na minha lista:
| Publicado no: | Mol Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Gene & Cell Therapy
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7854294/ https://ncbi.nlm.nih.gov/pubmed/33130313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.10.022 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|